WO2008019147A3 - Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen - Google Patents

Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen Download PDF

Info

Publication number
WO2008019147A3
WO2008019147A3 PCT/US2007/017621 US2007017621W WO2008019147A3 WO 2008019147 A3 WO2008019147 A3 WO 2008019147A3 US 2007017621 W US2007017621 W US 2007017621W WO 2008019147 A3 WO2008019147 A3 WO 2008019147A3
Authority
WO
WIPO (PCT)
Prior art keywords
concentration
fibrinogen
agonists
altering
exendins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/017621
Other languages
French (fr)
Other versions
WO2008019147A2 (en
Inventor
Dennis Kim
Michael Trautmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Eli Lilly and Co
Original Assignee
Amylin Pharmaceuticals LLC
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals LLC, Eli Lilly and Co filed Critical Amylin Pharmaceuticals LLC
Priority to US12/375,734 priority Critical patent/US8501693B2/en
Priority to EP07836618A priority patent/EP2066337A2/en
Publication of WO2008019147A2 publication Critical patent/WO2008019147A2/en
Anticipated expiration legal-status Critical
Publication of WO2008019147A3 publication Critical patent/WO2008019147A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to altering the concentration of fibrinogen, specifically, for example, by decreasing fibrinogen concentration. The present invention also relates to methods for improving the cardiovascular risk profile of a subject by decreasing fibrinogen concentration.
PCT/US2007/017621 2006-08-04 2007-08-06 Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen Ceased WO2008019147A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/375,734 US8501693B2 (en) 2006-08-04 2007-08-06 Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen
EP07836618A EP2066337A2 (en) 2006-08-04 2007-08-06 Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83543606P 2006-08-04 2006-08-04
US60/835,436 2006-08-04

Publications (2)

Publication Number Publication Date
WO2008019147A2 WO2008019147A2 (en) 2008-02-14
WO2008019147A3 true WO2008019147A3 (en) 2009-06-11

Family

ID=39033523

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/017621 Ceased WO2008019147A2 (en) 2006-08-04 2007-08-06 Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen

Country Status (3)

Country Link
US (1) US8501693B2 (en)
EP (1) EP2066337A2 (en)
WO (1) WO2008019147A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
KR101241862B1 (en) * 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 Novel glp-1 derivatives
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
MX2008014870A (en) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Two-piece, internal-channel osmotic delivery system flow modulator.
EP2049081B1 (en) 2006-08-09 2012-11-14 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
HRP20130259T1 (en) 2007-04-23 2013-04-30 Intarcia Therapeutics, Inc. SUSPENSION FORMULATIONS OF INSULINOTROPIC PEPTIDES AND THEIR USE
JP2009019027A (en) * 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd Insulin-secreting peptide derivatives with amino-terminal amino acid mutations
DK2240155T3 (en) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Devices, formulations and methods for the delivery of several beneficial agents
WO2009109927A2 (en) * 2008-03-05 2009-09-11 Tel Hashomer Medical Research Infrastructure And Services Ltd. Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
SMT201700583T1 (en) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US9168288B2 (en) * 2010-04-09 2015-10-27 Mount Sinai Hospital Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2678002A2 (en) 2011-02-25 2014-01-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
US20130090285A1 (en) * 2011-06-27 2013-04-11 Phasebio Pharmaceuticals, Inc. Methods of treatment with glp-1 receptor agonists
EP2750697A4 (en) 2011-09-02 2015-03-25 Medtronic Inc CHIMERIC NATRIURETIC PEPTIDE COMPOSITIONS AND PREPARATION METHODS
CN103408669B (en) * 2013-08-01 2016-01-20 江苏泰康生物医药有限公司 GLP-1 analog fusion, and its production and use
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
EP3824903A1 (en) * 2015-09-30 2021-05-26 IGM Biosciences Inc. Binding molecules with modified j-chain
RU2760007C2 (en) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Polypeptides selective to glucagon receptors and their application methods
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
US12098202B2 (en) 2016-10-10 2024-09-24 The National Institute for Biotechnology in the Negev Ltd. Non-cytotoxic modified cells and use thereof
CN110225762A (en) 2017-01-03 2019-09-10 因塔西亚制药公司 The method of the co-administration of continuous administration and drug including GLP-1 receptor stimulating agent
TWI829687B (en) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
TWI705820B (en) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1 agonist compositions
CA3154744A1 (en) 2019-11-06 2021-05-14 Sarah FRIEDRICH Glp-1 receptor agonists in dementia
WO2024132147A1 (en) * 2022-12-22 2024-06-27 Lifearc Galanin-2 receptor agonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050101537A1 (en) * 1997-01-07 2005-05-12 Beeley Nigel Robert A. Use of exendins and agonists thereof for lowering plasma lipid

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO1998043658A1 (en) 1997-03-31 1998-10-08 Eli Lilly And Company Glucagon-like peptide-1 analogs
US7220721B1 (en) 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US6552167B1 (en) 1998-08-28 2003-04-22 Gryphon Therapeutics, Inc. Polyamide chains of precise length
US6569832B1 (en) 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
US7144863B2 (en) * 2001-06-01 2006-12-05 Eli Lilly And Company GLP-1 formulations with protracted time action
EP1569682A2 (en) * 2002-12-03 2005-09-07 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
JP2007537142A (en) 2003-12-18 2007-12-20 ノボ　ノルディスク　アクティーゼルスカブ Novel GLP-1 analogues bound to albumin-like substances
PT1881850E (en) 2005-05-13 2010-11-26 Lilly Co Eli Glp-1 pegylated compounds
US20100029903A1 (en) 2005-12-14 2010-02-04 Novo Nordisk A/S Polypeptide Protracting Tags

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050101537A1 (en) * 1997-01-07 2005-05-12 Beeley Nigel Robert A. Use of exendins and agonists thereof for lowering plasma lipid

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
COURRÈGES ET AL: "Liraglutide treatment, blood pressure and biomarkers of cardiovascular risk in patients with type 2 diabetes: 14 weeks monotherapy study", DIABETOLOGIA (SUPPLEMENT 1), vol. 49, September 2006 (2006-09-01), pages 4, XP002524013 *
DEACON: "Therapeutic strategies based on glucagon-like peptide 1", DIABETES, vol. 53, 2004, pages 2181 - 2189, XP002524064 *
GARDINER ET AL: "Mesenteric vasoconstriction and hindquarters vasodilatation accompany the pressor actions of exendin-4 in conscious rats", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 316, February 2006 (2006-02-01), pages 852 - 859, XP002524063 *
HOOD ET AL: "Use of exenatide in patients with type 2 diabetes", DIABETES SPECTRUM, vol. 19, July 2006 (2006-07-01), pages 181 - 186, XP002524062 *
KAPITZA ET AL: "Long-term treatment with exenatide improved post-prandial glycaemic control and was associated with a shift from small to large HDL and LDL particles", DIABETOLOGIA (SUPPLEMENT 1), vol. 49, September 2006 (2006-09-01), pages 140 - 141, XP002524010 *
LINNEBJERG ET AL: "Exenatide delays gastric emptying and reduces post-prandial glucose in type 2 diabetes", DIABETOLOGIA (SUPPLEMENT 1), vol. 49, September 2006 (2006-09-01), pages 140, XP002524012 *
TUTUNCU ET AL: "Exendin-4 rapidly activates eNOS and protects human coronary artery endothelial cells against glucolipoapoptosis", DIABETOLOGIA (SUPPLEMENT 1), vol. 49, September 2006 (2006-09-01), pages 146, XP002524011 *

Also Published As

Publication number Publication date
WO2008019147A2 (en) 2008-02-14
US20100144621A1 (en) 2010-06-10
EP2066337A2 (en) 2009-06-10
US8501693B2 (en) 2013-08-06

Similar Documents

Publication Publication Date Title
WO2008019147A3 (en) Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
WO2008008887A3 (en) Gpr119 agonists for treating metabolic disorders
WO2007056681A3 (en) Methods for administering hypoglycemic agents
WO2008121616A3 (en) Antibodies with decreased deamidation profiles
WO2008070692A8 (en) Bicyclic compounds and use as antidiabetics
WO2006105338A3 (en) Fc VARIANTS WITH OPTIMIZED PROPERTIES
WO2010077898A3 (en) Trans-chloro-3,3,3-trifluoropropene for use in chiller applications
WO2007003962A3 (en) Gpcr agonists
WO2007003961A3 (en) Gpcr agonists
WO2011056713A3 (en) Glp-1 receptor agonist compounds for obstructive sleep apnea
IL183940A0 (en) Glp-1 agonists, compositions, methods and uses
PL2134329T3 (en) Composition and microsphere for controlled-release of exendin, and method of preparing the same
WO2011075636A3 (en) Wise binding agents and epitopes
WO2009070243A3 (en) Wise binding antibodies and epitopes
EA200970580A1 (en) TANNA BROADBAND
PL2018184T3 (en) Anti-VEGF-B antibody for the treatment or prophylaxis of diabetes type II or metabolic syndrome
WO2010015657A3 (en) Alkoxypyrazoles and the process for their preparation
WO2010005982A3 (en) Multiplexed biomarkers of insulin resistance
WO2010118866A8 (en) Trehalulose-containing composition, its preparation and use
GB0812642D0 (en) Compounds
WO2010072420A3 (en) Compositions comprising hemp oil for treating topical diseases, especially hand-foot syndrome
WO2008136394A1 (en) Method for production of lactam compound, and intermediate for the production method
WO2006110887A3 (en) Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling
WO2008085982A3 (en) Methods and compositions for treating hypoglycemic disorders
WO2010077976A3 (en) Prokineticin receptor antagonists and uses thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007836618

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07836618

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12375734

Country of ref document: US